At about $35.6 billion raised by med-tech companies, the first half of 2020 has already pulled in more than the full-year totals for 2017 and 2018 and is at about 87% of what was raised in 2019. Most of the money is coming through private financings of public companies, including large notes offerings and private placements, as well as follow-on offerings.

Research focused on finding viable solutions to counter the COVID-19 pandemic continues at an explosive pace with a total of 588 potential therapeutics and vaccines at the forefront of scientific efforts launched by industry, academia and government.